TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Persistent Pulmonary Hypertension in Neonates With Nebulized Magnesium Sulfate

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newborns with documented persistent pulmonary hypertension as confirmed by echocardiography.~* Neonates born at ≥ 35 wk. gestation with a birth weight of 2.5-4 kg~* Neonates have to be connected to mechanical ventilation with an oxygenation index (OI) \>30 on two occasions at least 15 min apart.~* The echocardiogram had to show a predominant right-to-left or bidirectional shunt (through ductus arteriosus and/or foramen oval) and/or tricuspid regurgitant jet with a pressure gradient ≥ 2/3 of the systemic systolic blood pressure.~Exclusion Criteria:~* Infants of parents who refuse to give informed consent.~* Infants of mothers who receive magnesium sulfate within 48 h before labor.~* Congenital heart diseases other than patent ductus arteriosus (PDA) and foramen ovale.~* Major congenital anomalies, including congenital diaphragmatic hernia and lung hypoplasia.~* Prior need for cardiopulmonary resuscitation~* Mean arterial blood pressure (MABP) \< 35 mmHg despite therapy with volume infusions and vasoactive inotropes.~* Impaired kidney function; and prior administration of pulmonary vasodilators or prior administration of surfactant.

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 3 Days
- Healthy Volunteers: f

Study Arms:
- Nebulized magnesium (NebMag) group 1 (Type: ACTIVE_COMPARATOR): NebMag group (n=20) was administered nebulized isotonic magnesium (64 mg/mL). For nebulization, an isotonic MgSO₄ solution (64 mg/mL) was formulated by diluting a 10% intravenous preparation of MgSO₄ heptahydrate with sterile distilled water. 4 mL aliquots of the isotonic MgSO₄ solution (containing 256 mg of MgSO₄) were administered every 15 minutes through the jet nebulizer connected to the ventilator during the 24 hour study period.
- Intravenous magnesium (IVMag) group 2 (Type: ACTIVE_COMPARATOR): IVMag group (n=20) received intravenous magnesium. For intravenous administration, a 10% MgSO₄ solution was prepared by diluting a 50% intravenous formulation of MgSO₄ heptahydrate with 5% glucose and administrated in a loading dose of 2 mL/kg over 30 minutes (equivalent to 200 mg/kg of MgSO₄), followed by a continuous infusion at a rate of 0.5 mL/kg/h (equivalent to 50 mg/kg/h of MgSO₄) over the 24 hour study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients who are at least 6 years of age and who will not have reached their 12th birthday~* Diagnosis of ADHD~* Normal intelligence~Exclusion Criteria:~* Weigh less than 20 kg or more than 60 kg at study entry~* Other relevant psychiatric diagnoses~* Are at serious suicidal risk as determined by the investigator~* Have a history of severe allergies~* Alcohol or drug abuse within the past 3 months

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects age 18-80 (inclusive) with confirmed diagnosis of OHT or OAG~* Confirmed diagnosis of bilateral OHT or chronic open-angle glaucoma~* Able to undergo washout of all ocular drugs~* An IOP ≥ 22mmHg at 8:00 AM and ≥ 21 mmHg at 10:00 AM in at least one eye; but ≤ 35 mmHg at all time points in both eyes on Day -2 and Day -1~* Central corneal thickness 500-600 µm at screening in both eyes~* BCVA 20/100 or better in both eyes~Exclusion Criteria:~* Any history of severe ocular trauma in either eye at any time~* Any history of previous intraocular or ocular laser surgery within the past 3 months or any refractive surgery procedure within the past 6 months of screening visit in the study eye(s)~* Cataracts that prevent observation of the fundus in either eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Arm 1 (Type: EXPERIMENTAL): Experimental Eye drops 3.0 µg/mL QD both eyes on Day 1, 5-18
- Experimental Arm 2 (Type: EXPERIMENTAL): Experimental Eye drops 10.0 µg/mL QD both eyes on Day 1, 5-18
- Experimental Arm 3 (Type: EXPERIMENTAL): Experimental Eye drop 30.0 µg/mL QD both eyes on day 1, 5-18
- Experimental Arm 4 (Type: EXPERIMENTAL): Experimental Eye drop, 2 sequence crossover Cohort \[1 dose; 1-30 µg/mL\]to be determined and placebo
- Placebo Arm (Type: PLACEBO_COMPARATOR): Matched placebo eye drops dosed in same manner as ONO-9054

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Aggressive Hydration Versus Rectal Indomethacin for Prevention of Post-ERCP Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients aged 18 to 70 years undegoingt ERCP for the first time~* Patients undergoing ERCP for standard clinical indications~Exclusion Criteria:~* Ongoing acute pancreatitis~* Known chronic calcific pancreatitis~* Pancreatic head mass~* Any malignancy~* Standard contraindications to ERCP~* Unwillingness or inability to consent for the study~* Ongoing hypotension including those with sepsis~* Cardiac insufficiency (CI, \>NYHA Class II heart failure)~* Renal insufficiency (RI, creatinine clearance \<40mL/min)~* Severe liver dysfunction (albumin \< 3mg/dL)~* Respiratory insufficiency (defined as oxygen saturation \< 90%)~* Greater than 70 years of age~* Pregnancy~* Breastfeeding mother~* Allergy/hypersensitivity to aspirin or NSAIDs~* Received NSAIDs in prior 7 days (aspirin 325mg or less ok)~* Active or recurrent (within 4 weeks) gastrointestinal hemorrhage~* Hyponatremia (Na+ levels \< 135mEq/L))~* Hypernatremia (Na+ levels \> 150mEq/L) will be excluded.~* Edema or anasarca~* Ascites~* Procedure performed on major papilla/ventral pancreatic duct in patient with pancreas divisum (dorsal duct not attempted on injected)~* ERCP for biliary stent removal or exchange without anticipated pancreatogram~* Subject with prior biliary sphincterotomy now scheduled for repeat biliary therapy without anticipated pancreatogram~* Anticipated inability to follow protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Aggressive Hydration (Type: EXPERIMENTAL): Patients randomized to the aggressive intravenous hydration group received Lactated Ringers solution (LR) \[COMPOUND SODIUM LACTATE INJECTION I.P.,INVEN PHARMACEUTICALS PVT.LTD,MP,INDIA\] intravenously (IV) at 3 mL/kg/hr during the ERCP, a 20cc/kg IV bolus immediately afterward, and then at 3 mL/kg/hr for 8 hours following the procedure.
- Rectal Indomethacin (Type: ACTIVE_COMPARATOR): Patients randomised to Rectal Indomethacin were administered a suppository of 100 mg of indomethacin \[Indomethacin Suppository 100 Mg B.P, GALEN PHARMACEUTICAL LTD, GUJRAT, INDIA\] just after the completion of ERCP procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy adult Japanese male between the age of 20-40~* body mass index between 18.5-25~Exclusion Criteria:~* clinically significant abnormal physical examination, vital signs or electrocardiogram~* use of any prescription medication, antacid, nutritional supplement, vitamin preparation, or herb-containing drug within the previous 4 weeks~* use of any non-prescription medication within the previous 1 week~* history of drug or alcohol abuse

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Rabeprazole sodium Tablets, 5 mg (Type: EXPERIMENTAL): None
- Rabeprazole sodium Tablets, 10 mg (Type: EXPERIMENTAL): None
- Rabeprazole sodium Tablets, 20 mg (Type: EXPERIMENTAL): None
- Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 65 years and older~* Having a friend/relative willing to serve as a Knowledgeable Informant (KI)~* Diagnosis of aMCI-MD~* Self-identified as African American~Exclusion Criteria:~* Psychiatric diagnosis, including dementia and major depression~* Sensory deficits that preclude neuropsychological testing~* Institutional residence~* Reduced life expectancy due to known terminal illness

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Behavior Activation (Type: EXPERIMENTAL): BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
- Supportive Therapy (ST) (Type: PLACEBO_COMPARATOR): ST is a person-centered treatment in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female and is at least 18 years of age; scheduled to receive his or her first course of cisplatin chemotherapy at a dose of 70 mg/m2 or higher; predicted life expectancy of 3 months or greater~* Patient is post menopausal or, if premenopausal, must use double-barrier contraception~Exclusion Criteria:~* Patient has symptomatic primary or metastatic CNS malignancy~* Patient has received or will receive Radiation therapy to the abdomen or pelvis in the week prior to Treatment Day 1 though Day 6~* Patient has vomited in the 24 hours prior to treatment Day 1~* Patient has an active infection; Patient uses illicit drugs or has current evidence of alcohol abuse~* Patient is pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Arm 1: study medication
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: Active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: French National Registry of Children Born Small for Gestational Age Treated With Somatropin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Born small for gestational age

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I (Type: None): None
- Phase II (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form~* Age ≥18 years~* Histologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease~  o Patients with breast cancer overexpressing HER2 are not eligible.~* Availability of tumor tissue, either archival FFPE or obtained at study entry through fresh biopsy~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* All acute treatment-related toxicity from prior therapy must have resolved to Grade ≤ 1 prior to study entry~* Adequate hematologic and end-organ function~* Evaluable or measurable disease per RECIST v1.1~* For women of childbearing potential, agreement to use two effective forms of contraception~Exclusion Criteria:~* Known significant dose delays during prior treatment with a taxane due to drug-related toxicities~* Prior treatment with more than two regimens of systemic cytotoxic chemotherapy for locally recurrent or metastatic disease~* Treatment with any anti-cancer therapy within 3 weeks prior to initiation of study treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Vantictumab combined with paclitaxel (Type: EXPERIMENTAL): Drug: vantictumab combined with paclitaxel - administered intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Men 50 years or older~2. with LUTS \[defined as International Prostate Symptom Score (IPSS) \>= 10\].~3. Stage 1 or 2 essential hypertension (SBP \>= 140 mm Hg and \< 180 mm Hg and/or DBP \>= 90 mm Hg and \< 110 mm Hg)~Exclusion Criteria:~1. A history of postural hypotension~2. Secondary hypertension~3. Prostate cancer~4. Prostate surgery or other intervention~5. Use of any agents to influence the LUTS symptoms in the last 4 weeks~6. Other severe diseases

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of DSA on Recovery of Anaesthesia in Children (Het Effect Van DSA Op Het Herstel Na Anesthesie Bij Kinderen).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent of parents/guardians~* Age ≥6 months and ≤12 years~* Surgical procedure requiring GA supplemented with caudal analgesia~* Ability of the parents/guardians to communicate in Dutch~Exclusion Criteria:~* Primary exclusion criteria~* Withdrawal of informed consent~* (Chronic) use of drugs influencing the electroencephalogram~* Use of premedication~* Known intolerance for sevoflurane~* Parents/guardians unable to communicate in Dutch~* Secondary exclusion criteria~* Protocol violation~* Data registration failure

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): In patients randomised to the control group, sevoflurane will be titrated according to a Minimal Alveolar Concentration (MAC) of 0.9 respectively an end tidal sevoflurane concentration of 2.3% based on standard practice in our paediatric anaesthesia department.
- Treatment (Type: EXPERIMENTAL): In patients randomised to the intervention group of the trial, the anaesthetic agent sevoflurane will be titrated according to the typical DSA pattern for general anaesthesia with sevoflurane, provided by the Narcotrend

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Centered-Rehabilitation ver111090.1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals with intact cognitive functioning.~2. Participants will be age 50 or older.~Exclusion Criteria:~1. Individuals with a documented history of cognitive impairment.~2. A history of serious mental illness (e.g., bipolar disorder, schizophrenia, axis 2 disorders)~3. Sensory or motor impairments that limit the ability to take part in the study~4. A significant history or current use of alcohol or drug abuse/dependence~5. Those who are currently pregnant (if there is a question of pregnancy, pregnancy tests will be available for participants at no charge)~6. Participants with an Mini Mental State Examination score \<24 at screening.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Active HD-tDCS (Type: ACTIVE_COMPARATOR): Participants will receive real HD-tDCS (3 milliamps for 20 minutes) for a single session.
- Sham HD-tDCS (Type: SHAM_COMPARATOR): Participants will undergo the exact same procedures as the active group but will receive sham stimulation for a single session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Galcanezumab In Participants With Episodic Cluster Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of cluster headache as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines with a history of episodic cluster headache with at least two cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of \>=1 month.~* Participants are able to distinguish cluster headache attacks from other headaches.~Exclusion Criteria:~* Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device.~* Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).~* Are taking indomethacin and/or are suspected of having another distinct trigeminal autonomic cephalalgia.~* A history of migraine variants that could implicate or could be confused with ischemia.~* Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins.~* A history or presence of other medical illness that indicates a medical problem that would preclude study participation.~* Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator.~* Women who are pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Galcanezumab 300mg (Type: EXPERIMENTAL): Galcanezumab 300mg administered subcutaneously (SC) every 30 days during an 8 week treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC every 30 days during an 8 week treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial on Palliative Cancer Patients With Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severity of constipation \> 3 points (an 8-point scale from 0 to 7)~* Palliative Performance Scale ≥60%~* Relatively stable liver and renal function within 3 months~* Patients who can read and speak Chinese~Exclusion Criteria:~* Inability to communicate~* Presence of a colostomy, or gastrointestinal obstruction~* Presence of loose or watery stool (Bristol stool scale 6-7) or bowel movement \> 3/day under routine laxative treatment~* History of Chinese herbal medicine allergies~* Estimated life expectancy less than 1 month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chinese herbal medicine (Type: EXPERIMENTAL): MaZiRenWan 10g plus HuangQi 20g are chosen as the core prescription. Furthermore, six herbal granules can be added according to the syndrome differentiated for individual participant. They are ShuDiHuang 15g and Danggui 10g for deficiency of blood, Maidong 15g and ShengDiHuang 10g for deficiency of Yin, and RouCongRong 15g and Niuxi 10g for deficiency of Yang.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%), and caramel (0.34%) to achieve color, smell, taste, and texture comparable to the herbal granules.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete